Literature DB >> 35778612

T-DXd active in HER2-low disease.

Peter Sidaway1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35778612     DOI： 10.1038/s41571-022-00663-9

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   65.011


× No keyword cloud information.
  1 in total

1.  Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.

Authors:  Shanu Modi; William Jacot; Toshinari Yamashita; Joohyuk Sohn; Maria Vidal; Eriko Tokunaga; Junji Tsurutani; Naoto T Ueno; Aleix Prat; Yee Soo Chae; Keun Seok Lee; Naoki Niikura; Yeon Hee Park; Binghe Xu; Xiaojia Wang; Miguel Gil-Gil; Wei Li; Jean-Yves Pierga; Seock-Ah Im; Halle C F Moore; Hope S Rugo; Rinat Yerushalmi; Flora Zagouri; Andrea Gombos; Sung-Bae Kim; Qiang Liu; Ting Luo; Cristina Saura; Peter Schmid; Tao Sun; Dhiraj Gambhire; Lotus Yung; Yibin Wang; Jasmeet Singh; Patrik Vitazka; Gerold Meinhardt; Nadia Harbeck; David A Cameron
Journal:  N Engl J Med       Date:  2022-06-05       Impact factor: 176.079
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.